A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Meet with Modular Medical CEO, Jeb BesserObesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart AssociationAbout half of all patients prescribed a GLP-1 drug for weight loss discontinued after...
Encinitas, California--(November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key...
PONTE VEDRA, Fla., Nov. 7, 2024 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior anticoagulation for...
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven...
DUBLIN, Nov. 07, 2024 -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that on November 6, 2024, it received...
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery- Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone-Findings suggest that pump...
Record Net Revenues of $35.3 million Representing 11% Growth from the Prior Year Net income of $1.8 million, an increase of 162% Adjusted EBITDA (non-GAAP) margin expanded by 2.8% to 22% Reaffirms Full-Year 2024 Guidance ROCHESTER HILLS, Mich. - InfuSystem Holdings,...
DENVER, CO / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the...
CARMEL, Ind., Nov. 05, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized...
Clearance expands indication for use from 11-18 year olds to 8-21 year olds; and from 3 devices, not to exceed 4 weeks, to 1 device per week for 4 weeksCARMEL, Ind., Nov. 04, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical...